NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Armstrong, Deborah K.; Alvarez, Ronald D.; Backes, Floor J.; Bakkum-Gamez, Jamie N.; Barroilhet, Lisa; Behbakht, Kian; Berchuck, Andrew; Chen, Lee-may; Chitiyo, Viola C.; Cristea, Mihaela; DeRosa, Maria C.; Eisenhauer, Eric L.; Gershenson, David M.; Gray, Heidi J.; Grisham, Rachel N.; Hakam, Ardeshir; Jain, Angela; Karam, Amer; Konecny, Gottfried E.; Leath, Charles A.; Leiserowitz, Gary S.; Liu, Joyce F.; Martin, Lainie P.; Matei, Daniela; McHale, Michael; McLean, Karen; Miller, David S.; Percac‐Lima, Sanja; Remmenga, Steven W.; Schorge, John O.; Stewart, Daphne; Thaker, Premal H.; Vargas, Roberto; Hendrickson, Andrea Wahner; Werner, Theresa L.; Zsíros, Emese; Dwyer, Mary A.; Hang, Lisa E

doi:10.6004/jnccn.2022.0047

Cited by 202 publications

(130 citation statements)

References 42 publications

Supporting

Mentioning

129

Contrasting

Order By: Relevance

“…For direct application to cancer cells on the peritoneum, IP infusion using anticancer drugs with lower absorption and systemic toxicity, such as paclitaxel and docetaxel, has been studied in various cancers. It is considered effective and safe in treating peritoneal cancer dissemination from ovarian cancer [ 441 442 443 444 445 446 447 ].…”

Section: Treatment For Far Advanced Gastric Cancermentioning

confidence: 99%

Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

et al. 2023

View full text Add to dashboard Cite

Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this is the 4th gastric cancer guideline published in Korea which is the revised version of previous evidence-based approach in 2018. Current guideline is a collaborative work of the interdisciplinary working group including experts in the field of gastric surgery, gastroenterology, endoscopy, medical oncology, abdominal radiology, pathology, nuclear medicine, radiation oncology and guideline development methodology. Total of 33 key questions were updated or proposed after a collaborative review by the working group and 40 statements were developed according to the systematic review using the MEDLINE, Embase, Cochrane Library and KoreaMed database. The level of evidence and the grading of recommendations were categorized according to the Grading of Recommendations, Assessment, Development and Evaluation proposition. Evidence level, benefit, harm, and clinical applicability was considered as the significant factors for recommendation. The working group reviewed recommendations and discussed for consensus. In the earlier part, general consideration discusses screening, diagnosis and staging of endoscopy, pathology, radiology, and nuclear medicine. Flowchart is depicted with statements which is supported by meta-analysis and references. Since clinical trial and systematic review was not suitable for postoperative oncologic and nutritional follow-up, working group agreed to conduct a nationwide survey investigating the clinical practice of all tertiary or general hospitals in Korea. The purpose of this survey was to provide baseline information on follow up. Herein we present a multidisciplinary-evidence based gastric cancer guideline.

show abstract

Section: Treatment For Far Advanced Gastric Cancermentioning

confidence: 99%

Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Any time a pelvic ultrasound detects an adnexal lesion, Armstrong et al (6) determining whether the lesion is benign or precancerous is important for guiding subsequent care, which may involve referral to a gynecologic oncologist.…”

Section: Discussionmentioning

confidence: 99%

Study of Validity of O-RADS Ultrasonography in Risk Stratification and Management of Adnexal Masses

Ahmed¹,

Alrahman²,

Esmaiyl³

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: It is important to remember that ovarian cancer is a frequent and potentially fatal disease. For the purpose of characterizing the imaging properties of adnexal masses, the Ovarian-Adnexal Reporting and Data System (O-RADS) Committee have been established. Objective: The aim of the current work was to evaluate the validity of O-RADS to diagnose adnexal masses utilizing pelvic ultrasound. Subjects and methods: This prospective cohort study included a total of 30 women having at least one adnexal mass detected by US, recruited from Department of radiodiagnosis, Zagazig University Hospitals. Results: About 75.8% of the adnexal masses were benign and 24.2% were malignant. The most frequent benign lesion among patients who had O-RADS 2 or 3 was a hemorrhagic cyst. Only 2 patients with O-RADS 5 had benign lesions (mucinous cystadenoma and serous cystadenoma), while 5 patients had malignant lesions. Regarding only those adnexal masses classified as O-RADS 5 to predict adnexal masses malignancy, the O-RADS had a specificity, sensitivity,

show abstract

“…The LION study suggested that lymphadenectomy did not result in longer PFS or OS in patients with advanced ovarian cancer when there were no clinically suspicious abnormal lymph nodes. According to LION, systemic lymphadenectomy does not provide a survival bene t for patients with advanced ovarian cancer whose lymph nodes are visual normal, but increases the risks and complications of surgery; Systematic lymphadenectomy should not be routinely performed in these patients and international guidelines have been rewritten as a result (20).…”

Section: Discussionmentioning

confidence: 99%

Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort

Sun

Jiang

2023

Preprint

View full text Add to dashboard Cite

Background As ovarian clear cell carcinoma (OCCC) has distinct clinical features, biology, genetic characteristics and mechanisms of pathogenesis, and whether the origin of endometriosis or not affects the prognosis of OCCC remains controversial. Methods We retrospectively collected medical records and follow-up data of patients with OCCC treated at the Obstetrics and Gynecology Hospital of Fudan University from January 2009 to December 2019. Further, we divided patients into 2 groups. Group 1: non-endometriosis origin; Group 2: endometriosis origin. Clinicopathological characteristics and survival outcomes were compared between the 2 groups. Results A total of one hundred and twenty-five patients with ovarian clear cell carcinoma were identified and included. In the overall patients’ population, the 5-year overall survival was 84.8%, the mean overall survival was 85.9 months. The results of the stratified analysis showed that early stage (FIGO stage I/II) OCCC had a good prognosis. The results of univariate analyses indicated that a statistically significant relationship between overall survival (OS) and FIGO stage, lymph node metastasis, peritoneum metastasis, chemotherapy administration methods, Chinese herbal treatment, molecular target therapy. As for progression-free survival (PFS), a significant relationship between PFS and child-bearing history, largest residual tumor size, FIGO stage, tumor maximum diameter, lymph node metastasis was found, respectively. FIGO stage and lymph node metastasis are common poor prognostic factors affecting OS and PFS. The multivariate regression analysis revealed that FIGO stage (p = 0.028; HR, 1.944; 95% CI, 1.073–3.52) and treatment by Chinese herbs (p = 0.018; HR, 0.141; 95% CI, 0.028–0.716) were identified as influencing factors with regard to survival. The presence or absence of lymphadenectomy did not affect OS of 125 OCCC patients (p = 0.851; HR, 0.825; 95% CI, 0.111–6.153).

show abstract

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Cited by 202 publications

References 42 publications

Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

Study of Validity of O-RADS Ultrasonography in Risk Stratification and Management of Adnexal Masses

Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort

Contact Info

Product

Resources

About